In accordance with our results, a recent meta-analysis conducted by Iacovelli R. et al [40] found that the incidence of all- and high-grades pneumonia in patients receiving mTOR inhibitors was 10.4% and 2.4%, respectively. The gene discussed is MTOR; the disease is susceptibility to pneumonia measurement.